TITLE

Review: Amiodarone is effective for converting atrial fibrillation to sinus rhythm: COMMENTARY

AUTHOR(S)
Newman, David
PUB. DATE
January 2004
SOURCE
ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a study regarding effectiveness of amiodarone for conversion of atrial fibrillation (AF) to sinus rhythm, published in the 2003 issue of the journal "Archives of Internal Medicine." Clinically, one can divide AF into presentations where treatment priorities differ between rhythm control on the one hand and stroke prevention on the other. Usually, rhythm control is a priority in emergency departments, where intravenous or loading-dose oral medications are required, and a relevant outcome is acute conversion. Stroke prevention is a priority when cardioversion is more elective, and a separate strategy for reducing stroke risk is used before conversion. Drug-drug comparison trials are needed to guide clinicians in choosing among these potential management options.
ACCESSION #
12104533

 

Related Articles

  • Review: Amiodarone is effective for converting atrial fibrillation to sinus rhythm.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p6 

    This article focuses on a study regarding effectiveness of amiodarone for conversion of atrial fibrillation (AF) to sinus rhythm, published in the 2003 issue of the journal "Archives of Internal Medicine." For this study, published and unpublished randomized or quasirandomized clinical trials...

  • A New Drug for Rapid Conversion of Atrial Fibrillation. DiMarco, John P. // Clinical Cardiology Alert;May2008, Vol. 27 Issue 5, p37 

    VERNAKALANT IS A NEW INVESTIGATIONAL ANTI-arrhythmic drug. The compound is relatively selective, blocking the early-activating potassium channel and the frequency-dependent sodium channel. Vernakalant has a half-life of two to three hours. This study evaluates the ability of intravenous...

  • Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control? Yi-Gang Li; Hohnloser, Stefan H. // Journal of Cardiovascular Pharmacology & Therapeutics;Jun1998, Vol. 3 Issue 2, p185 

    The article discusses therapeutic alternatives for patients with persistent atrial fibrillation. It summarizes the present knowledge on this clinical problem with particular emphasis on issues such as efficacy of antiarrhythmic drugs to prevent recurrent atrial fibrillation, proarrhythmic...

  • Dronedarone: A Safety Comparison to Amiodarone. Clem, James R.; Farver, Debra K.; Fischer, Janet R.; Johnson, Thomas J. // Current Drug Safety;Jul2010, Vol. 5 Issue 3, p251 

    Dronedarone is an oral Class III antiarrhythmic agent which was recently approved by the US Food and Drug Administration for use in nonpermanent atrial fibrillation. Structurally similar to amiodarone, dronedarone is a benzofuran derivative but it lacks the iodine moiety attached to amiodarone....

  • Antiarrhythmics: the good the bad and the ugly in AF.  // Reactions Weekly;6/17/2006, Issue 1106, p5 

    Discusses research being done on the good and bad effects of antiarrhythmic medications taken during on atrial fibrillation episode. Reference to a study by C. Lafuente-Lafuente et al in the April 10, 2006 issue of "Archives of Internal Medicine"; Comparison of the long-term efficacy of at...

  • Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Nichol, G.; McAlister, F.; Pham, B.; Laupacis, A.; Shea, B.; Green, M.; Tang, A.; Wells, G. // Heart;Jun2002, Vol. 87 Issue 6, p535 

    Objective: To conduct a meta-analysis of randomized controlled trials to estimate the effectiveness of antiarrhythmic drugs at promoting sinus rhythm in patients with atrial fibrillation. Design: Articles were identified by using a comprehensive search of English language papers indexed in...

  • Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update. Tsuji, Yukiomi; Dobrev, Dobromir // Vascular Health & Risk Management;2013, Vol. 9, p165 

    Intravenous vernakalant has recently been approved in Europe as an atrial-selective antiarrhythmic drug for the conversion of recent-onset atrial fibrillation (AF). It inhibits atrial-selective K+ currents (IK,ACh and IKur) and causes rate-dependent atrial-predominant Na+ channel block, with...

  • Has the Time Come to Recommend Catheter Ablation of Atrial Fibrillation as First-Line Therapy? Calkins, Hugh // JAMA: Journal of the American Medical Association;2/19/2014, Vol. 311 Issue 7, p679 

    The author comments on a study published within the issue which compared catheter ablation of atrial fibrillation (AF) with antiarrhythmic drug therapy as first-line therapy for treatment of patients with symptomatic paroxysmal AF. He believes that the study has four clinical implications,...

  • AMIODARONE FOR THE TREATMENT OF PERSISTENT ATRIAL FIBRILLATION. Noble, S. L.; Replogle, William H.; Dickey, Sharon R. // Journal of Family Practice;May99, Vol. 48 Issue 5, p334 

    The article presents information on a study that examined the effectiveness of amiodarone in the restoration of sinus rhythm in patients with persistent atrial fibrillation (AF). For AF of greater duration, chemical cardioversion has been shown to have limited value. Amiodarone, a class III...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics